The pathways that allow quiescent disseminated cancer cells to survive during prolonged dormancy periods are unknown. Here, we identify the transcription factor ATF6␣ as a pivotal survival factor for quiescent but not proliferative squamous carcinoma cells. ATF6␣ is essential for the adaptation of dormant cells to chemotherapy, nutritional stress, and, most importantly, the in vivo microenvironment. Mechanism analysis showed that MKK6 and p38␣/␤ contribute to regulating nuclear translocation and transcriptional activation of ATF6␣ in dormant cancer cells. Downstream, ATF6␣ induces survival through the up-regulation of Rheb and activation of mTOR signaling independent of Akt. Down-regulation of ATF6␣ or Rheb reverted dormant tumor cell resistance to rapamycin and induced pronounced killing only of dormant cancer cells in vivo. Knocking down ATF6␣ also prolonged the survival of nude mice bearing dormant tumor cells. Targeting survival signaling by the ATF6␣-Rheb-mTOR pathway in dormant tumor cells may favor the eradication of residual disease during dormancy periods.
The pathways that allow quiescent disseminated cancer cells to survive during prolonged dormancy periods are unknown. Here, we identify the transcription factor ATF6␣ as a pivotal survival factor for quiescent but not proliferative squamous carcinoma cells. ATF6␣ is essential for the adaptation of dormant cells to chemotherapy, nutritional stress, and, most importantly, the in vivo microenvironment. Mechanism analysis showed that MKK6 and p38␣/␤ contribute to regulating nuclear translocation and transcriptional activation of ATF6␣ in dormant cancer cells. Downstream, ATF6␣ induces survival through the up-regulation of Rheb and activation of mTOR signaling independent of Akt. Down-regulation of ATF6␣ or Rheb reverted dormant tumor cell resistance to rapamycin and induced pronounced killing only of dormant cancer cells in vivo. Knocking down ATF6␣ also prolonged the survival of nude mice bearing dormant tumor cells. Targeting survival signaling by the ATF6␣-Rheb-mTOR pathway in dormant tumor cells may favor the eradication of residual disease during dormancy periods.
dormancy ͉ endoplasmic reticulum stress ͉ quiescence ͉ p38 ͉ MKK6 M inimal residual disease caused by solitary disseminated tumor cells (DTC) is a well recognized event associated with unfavorable patient prognosis (1, 2) . These cells, which usually stain negative for proliferation markers (e.g., Ki67) (3, 4) , may be the source of tumor recurrence that can develop up to decades after treatment of the primary tumor (3, 4) . These findings suggest that tumor cells may be able to reprogram into a quiescent behavior upon specific cues from the microenvironment (5) . This may result from growth arrest and survival programs that allow dormant tumor cells to resist therapy and survive for long periods of time. Understanding how dormant DTCs survive dissemination and therapy and persist in a viable state for prolonged periods is of fundamental clinical interest.
Despite clinical evidence that dormancy may arise from tumor cell quiescence, models that recapitulate such a behavior are scarce (5, 6) . We hypothesized that tumor cells able to reversibly acquire a nontumorigenic phenotype may recapitulate the programs of stress resistance that result in tumor cell quiescence. We previously identified a highly tumorigenic and metastatic human squamous carcinoma cell line (T-HEp3) that, when passaged in culture for Ͼ40 generations, reprograms into a reversible dormant phenotype (D-HEp3). This behavior is revealed upon inoculation of the cells in vivo and is durable for months (7) (8) (9) . Mechanistic studies showed that dormancy is due to a G 0 -G 1 arrest triggered in part by a low ERK/p38 signaling ratio and activation of the endoplasmic reticulum (ER) stress kinase PERK (10) . However, the signals responsible for the prolonged survival of these quiescent tumor cells in vivo had remained unknown.
The transcription factor ATF6 is an important survival mediator upon ER stress. Although D-HEp3 cells display an ER stress response characterized by PERK activation and chaperone upregulation (10), the role of ATF6 for these cells was unknown. Upon ER stress, ATF6, which is anchored to the ER membrane, translocates from the ER to the Golgi apparatus, where it is cleaved by S1P and S2P proteases (11) . The cytosolic domain of ATF6 then translocates into the nucleus and activates transcription of unfolded protein response genes. Unlike ATF6␤, ATF6␣ is required for cellular adaptation to acute and chronic ER stress in mouse embryonic fibroblasts (MEFs) (12) . These data suggest that ATF6␣ is an important mediator of survival upon ER stress required for cell and tissue homeostasis.
Little is known about the functional role of ATF6 isoforms in cancer. Query of the Oncomine (13) database showed that head and neck cancer patients whose primary tumors expressed higher ATF6 mRNA levels were more likely to be lymph node positive, which could be interpreted as a positive association with enhanced survival of DTC (14) . Similarly, a multicancer study showed higher ATF6 expression in metastases vs. primary lesions (15) , and colon cancer patients with increased expression of ATF6 in their primary tumors had higher chances of relapse (16) . This led us to hypothesize that ATF6␣ might mediate adaptation and survival either during quiescence or later during growth phases in secondary sites. We further hypothesized that our model of HEp3 carcinoma dormancy is amenable for testing such mechanisms. Here, we report that ATF6␣ serves as a basal and stress survival factor for dormant but not tumorigenic squamous carcinoma cells. We show further that ATF6␣ contributes to Rheb-mTOR pathway activation and rapamycin resistance and mediates survival signaling independently of Akt. Finally, we show that genetic ablation of ATF6␣ results in dormant cancer cell apoptosis and an extension of the dormancy period with delayed onset of recurrent growth.
Results

ATF6␣ Signaling Is Constitutive in Dormant but Not Malignant Vari-
ants of HEp3 Cells. We first analyzed ATF6 signaling in dormant D-HEp3 and tumorigenic T-HEp3 cells by monitoring the activity of a 5xATF6-GL3 Luciferase construct containing the ATF6 consensus binding site that had been previously used to measure ATF6 and XBP-1 signaling (see Materials and Methods and refs. 11 and 17). We found Ϸ10-fold-higher ATF6 reporter activation in D-HEp3 vs. T-HEp3 cells under basal conditions (Fig. 1A) . Furthermore, treatments with the ER stressors tunicamycin (Tm), thapsigargin (Tg), or DTT in serum-free media could further induce the ATF6 reporter activity in D-HEp3 cells, but only by Ϸ2-fold. These stressors had no effect on ATF6 reporter activity in T-HEp3 cells, suggesting that the low basal activity is not inducible. Using a siRNA that targets ATF6␣ in D-HEp3 cells, we could inhibit basal ATF6 reporter activation up to 50% and its Tm-inducibility almost completely (Fig. 1B) . A siRNA to XBP-1 only had a marginal effect on Tm-induced reporter activation [supporting information (SI) Fig. S1 A] . These results suggest that in D-HEp3 cells, the ATF6 reporter reflects mostly ATF6␣ and not XBP-1 activation.
To determine whether ATF6 is activated during adaptation to the tissue microenvironment, we monitored the ATF6 reporter in D-HEp3 and T-HEp3 cells inoculated in vivo on the chorioallantoic membrane (CAM) of live E9-E10 chicken embryos. This extraembryonic tissue provides a highly vascularized stromal microenvironment supportive of tumor cell survival and/or growth (7) . Inoculation of HEp3 cells on CAMs resulted in a 6-fold induction of ATF6 reporter activity after 24 h in vivo in both cell lines. At 48 h, this response persisted only in D-HEp3 cells (Fig. 1C) . This induction was much stronger than that obtained with ER stressors (6-fold versus 2-fold) suggesting that the in vivo microenvironment imposes high levels of stress that result in ATF6 signaling in both HEp3 cell lines. The persistent activation of ATF6 signaling in dormant tumor cells paralleled that observed for p38 in vivo (8, 9) . Activation of p38 is functionally linked to the quiescence and survival of dormant cells (8, 10) opening the question as to how ATF6 is regulated and whether it depends on p38 signaling.
Subcellular Localization and Activation of ATF6␣ in Quiescent HEp3
Cells Depends on p38 Signaling. We previously showed that D-HEp3 cell quiescence is largely due to high p38 and ER-stress signaling (10) . Thus, we measured expression levels, activation, localization, and p38 dependence of ATF6␣ in T-HEp3 and D-HEp3 cells. Western blots showed that basal full-length ATF6␣ levels were higher in D-HEp3 cells than in T-HEp3 cells and that processing into the cleaved nuclear form of ATF6␣ was more abundant in D-HEp3 than in T-HEp3 cells ( Fig. 2A) . Confocal microscopy and immunofluorescence (IF) revealed, that in D-HEp3 cells, ATF6␣ is predominantly localized in the nucleus (Fig. 2B, arrowhead) . In contrast, whereas some nuclear translocation is observed in THEp3 cells, ATF6␣ can also be prominently detected in their cytoplasm, a signal almost absent in D-HEp3 cells (Fig. 2B , arrow and 2C). These findings suggest that lower ATF6␣ nuclear translocation may reflect the low basal ATF6 reporter activity in T-HEp3 cells and that ATF6␣ might play a role in the D-HEp3 cell dormant phenotype.
Next, we determined whether ATF6␣ activation depends on p38 in D-HEp3 cells. Pharmacologic or genetic inhibition of p38 with 10 M SB203580, 10-20 M SCIO-469 (a specific p38␣ inhibitor) (18) , or siRNA to p38␣ resulted in a 50% reduction of ATF6 reporter activity, suggesting that ATF6␣ activity is at least in part p38␣/␤-dependent ( Fig. 2 D and E) . SB203580 treatment for 24 or 48 h also reduced ATF6␣ nuclear translocation in D-HEp3 cells (Fig. S1B) . Conversely, cotransfection of T-HEp3 cells that have low p38 activity (8) with a constitutively active MKK6b(E), an upstream activator of p38 (19) , significantly increased the percentage of cells with ATF6␣ nuclear localization ( (8, 21) . The siRNA to ATF6␣ persistently downregulated the ATF6␣ gene transcript, its target gene BiP ( Fig. 3A and Fig. S1D ), and ATF6␣ protein levels (Fig. 3B ). D-HEp3 cells stably expressing a shRNA to ATF6␣ after retroviral delivery also showed significant ATF6␣ mRNA knockdown (Fig. 3C) . We found that after 1 week in vivo, transient or stable RNAi targeting of ATF6␣ caused a statistically significant decrease in the number of viable cells per tumor nodule formed by D-HEp3 cells (Fig. 3D ). This suggests that whereas arrested control cells remain viable (8, 9) , D-HEp3 cells with ATF6␣ down-regulation are unable to survive in the new tissue microenvironment. ATF6␣ knockdown resulted in Ϸ3-fold higher cleaved caspase-3 levels in D-HEp3 cells as early as 24 h after in vivo inoculation (Fig. S1E ). ATF6␣ knockdown in the tumorigenic T-HEp3 cells did not affect apoptosis ( Fig. S1E and data not shown) and growth on CAMs (Fig.  3E ). This indicates that ATF6␣ is dispensable for T-HEp3 survival. The increased in vivo apoptosis of D-HEp3 cells with ATF6␣ down-regulation correlated with reduced ATF6 reporter activity 48 h after in vivo inoculation (Fig. 3F) . These results strongly suggest that survival of D-HEp3 cells in vivo critically depends on ATF6␣ signaling. (Fig. 3H) . Tumors originating from D-HEp3 cells expressing shATF6␣ had no detectable ATF6␣ knockdown as determined by RT-PCR (data not shown), suggesting a selection against low levels of this transcript. Taken together, our in vivo data support that ATF6␣ is a critical survival factor in dormant HEp3 cells. Its down-regulation causes in vivo apoptosis of dormant tumor cells, therefore significantly prolonging overall survival of mice carrying dormant disease.
ATF6␣ Mediates Survival Through Rheb and mTOR Independently of
Akt-Signaling. D-HEp3 cells display a chronic unfolded protein response (UPR) (10), suggesting that ATF6␣ activation is regulating a survival program under basal conditions. Gene expression profiling of D-HEp3 cells after ATF6␣ knockdown by siRNA, revealed 193 and 20 genes to be significantly up-and downregulated, respectively. As reported recently (12), ATF6␣ targets included genes in the general categories of protein folding, protein trafficking/secretion, protein degradation, and nutrient transport (Table S1 ). Knockdown of ATF6␣-regulated genes in these categories, including SCG II, SLC2A3 (Table S1) , and BiP/Grp78 did not significantly affect in vivo survival of D-HEp3 cells (data not shown). This suggested that other less obvious ATF6␣ target genes mediated the observed effect. The expression profiles revealed that ATF6␣ induces the expression of Ras homolog enriched in brain (Rheb), a critical activator of the mammalian target of rapamycin (mTOR), a pathway that propagates strong cell survival signals (22) . Rheb mRNA levels in the arrays were down-regulated 2-to 2.5-fold by ATF6␣ knockdown (Fig. 4A) , a result that was confirmed by Western blot analysis (Fig. 4A Inset) . This suggested that in D-HEp3 cells, ATF6␣ may signal for survival through a RhebmTOR pathway. We also found that Rheb expression levels in T-HEp3 cells are lower than in D-HEp3 cells and that levels of phosphorylated S6 ribosomal protein were reduced in T-HEp3 than D-HEp3 cells (Fig. 4B) . However, T-HEp3 cells showed higher p-Akt levels than D-HEp3 cells (Fig. 4B) . This suggested that D-HEp3 cells are able to achieve strong mTOR-S6 signaling through up-regulation of Rheb and by creating perhaps less dependence on active Akt. To explore the generality of Rheb-S6 regulation by ATF6␣, we compared WT vs. MKK6
Ϫ/Ϫ MEFs that show reduced ATF6␣ signaling (Fig. 2G) . We found MKK6
Ϫ/Ϫ
MEFs to have lower levels of Rheb and markedly decreased phosphorylation of S6 ribosomal protein (Fig. 4C Upper) , suggesting that the p38-ATF6␣-mTOR pathway can be active in murine cells. Expression of a constitutively active MKK6(E)b or overexpression of p38␣ (23) 
in MKK6
Ϫ/Ϫ cells resulted in higher Hsp27 phosphorylation and increased Rheb expression levels (Fig. 4C  Lower) . Accordingly, overexpression of ATF6 in HEK293 cells caused up-regulation of Rheb and increased phosphorylation of S6 ribosomal protein (Fig. 4D Left) . Conversely, stable or transient down-regulation of ATF6 (shRNA vs. siRNA) caused decreased phosphorylation of S6 ribosomal protein in D-HEp3 cells (Fig. 4D  Right and Fig. S1F ). Taken together, these data suggest that Rheb signaling to S6 ribosomal protein can be regulated by ATF6␣ and this is not only limited to the HEp3 model but may be operating to a certain extent in immortalized MEFs. The higher mTOR signaling in D-HEp3 cells is consistent with the markedly higher resistance of these cells to rapamycin when compared with T-HEp3, even at high concentrations of the drug (Fig. 4E) .
We next tested whether Rheb signaling is functionally linked to D-HEp3 cell survival. Although siRNAs to Rheb did not affect basal viability in T-or D-HEp3 cells, Rheb knockdown resulted in a sensitization to Tm in D-HEp3 cells only (Fig. 4F) . Also, both ATF6␣ and Rheb knockdown sensitized D-HEp3 cells to rapamycin, showing the importance of mTOR activation by an ATF6␣-Rheb signal (Fig. 4G ). In agreement with the hypothesis that ATF6␣ up-regulation of Rheb confers D-HEp3 cells with a selective survival advantage, knockdown of Rheb that also caused a reduction in p-S6 ribosomal protein phosphorylation (Fig. 4H Inset) resulted in a marked decrease only in D-HEp3 survival in vivo (Fig.  4H) . T-HEp3 cells remained unaffected by the siRNA to Rheb (Fig.  S1G) . All in all, this indicates that ATF6␣ is not only an important transducer of ER stress signals but also regulates Rheb signaling to promote survival. In D-HEp3 cells, this leads to stress resistance in vitro and prolonged survival in a dormant state in vivo.
Discussion
The present study demonstrates that in dormant carcinoma cells, ATF6␣ transduces survival signals through a ATF6␣-Rheb-mTOR pathway. We explored under which stimuli ATF6␣ may serve as a survival factor and found that like BiP (10), ATF6␣ signaling is important for protection against TOPO II inhibitors, ER, and low glucose stress. However, a very important function of ATF6␣ that diverged from BiP was that disruption of its signaling prevents dormant, but not proliferative, tumor cells to adapt to the in vivo microenvironment. ATF6 reporter measurements in vivo further substantiate this notion because both T-HEp3 and D-HEp3 cells activated the ATF6 reporter to the same extent, but only D-HEp3 cells maintained this activation. Thus, it is possible that although T-HEp3 cells might use ATF6␣ for the initial adaptation to the in vivo microenvironment, they ultimately do not rely on it for their expansion. This suggests that redundant survival signals overcome ATF6␣ deficiency in expanding tumor masses but that high ATF6␣-Rheb-mTOR signaling is a survival advantage under situations of adaptation such as tumor cell quiescence. The higher levels of ATF6␣ in D-HEp3 than in T-HEp3 cells are consistent with previous studies (10) showing that D-HEp3 cells display a UPR characterized by higher p-PERK, XBP-1 splicing, and chaperone expression that depend in part on p38␣/␤ activation (10) . Our data support that p38␣/␤ signaling is an important contributor, although not the only one, to ATF6␣ activation. Our results using MEFs with homozygous deletion for MKK6, and HEp3 cells, in which p38 activity was stimulated by an active MKK6 mutant or inhibited with SB203580 or SCIO-469, showed that ATF6␣ nuclear translocation and transcriptional activation depends on MKK6 and p38␣/␤ signaling. The p38␣ RNAi and SCIO-469 experiments further support that this particular isoform is required for ATF6␣ activation in D-HEp3 cells. These findings are in agreement with those in normal cells showing that p38 directly phosphorylates ATF6␣ to regulate chaperone expression (24, 25) . Our studies further define a contribution of MKK6 and at least p38␣ in the activation of ATF6␣ in dormant carcinoma cells. However, because BiP was not mediating the ATF6␣ survival signal in vivo, it became important to further identify the mechanism.
Our gene array and validation studies revealed that the GTPase Rheb was induced by ATF6␣. Rheb is an important mediator of survival linked to the sensing of nutritional stress and an immediate upstream activator of mTOR, a strong survival regulator in tumors (26, 27) . Knockdown of Rheb sensitized only D-HEp3 cells to Tm, reduced their Rapamycin-resistance, and, most importantly, resulted in a marked reduction in D-HEp3 cell survival in vivo. Unlike BiP or other genes involved in secretion or glucose transport (data not shown), which are major pathways regulated by ATF6␣ (12), Rheb might be an important regulator of ATF6␣-induced in vivo survival. D-HEp3 cells express higher levels of Rheb and display stronger S6 ribosomal protein phosphorylation than T-HEp3 cells. Furthermore, in MKK6 Ϫ/Ϫ MEFs with reduced ATF6␣ activity, Rheb protein levels and p-S6 were reduced, suggesting that transcriptional activation of ATF6␣ by MKK6-p38 is functional in murine cells for inducing Rheb expression and mTOR signaling. A distinguishing feature was that T-HEp3 cells have higher p-Akt levels than D-HEp3 cells, but S6 phosphorylation is still higher in the latter. This suggests that although in D-HEp3 cells Akt activation is low, probably because of low EGFR and FAK signaling (28), these cells are able to maintain strong mTOR activation and survival through an alternative induction of Rheb by ATF6␣.
There is limited evidence of the role of ATF6␣ in cancer. Our studies show that p38 signaling through ATF6␣, Rheb, and mTOR may have a prosurvival function in solid tumor cells, particularly during a quiescent phase. These findings may be of relevance because cancer patient gene expression profiling data in the Oncomine database (13) revealed a positive correlation between high ATF6 expression in head and neck and colorectal cancer primary tumors and the propensity of patients to develop lymph node metastasis (14) and relapse (16) (Fig. S2) . A weaker but similar trend was found for Rheb in head and neck cancer studies (29) (Fig.  S2) . It is possible that ATF6␣ and Rheb may have a survival function that allows dormant HNSCC cells to resist changes in the tissue microenvironment but also to survive nutritional or chemotherapy-induced stress. The latter is substantiated by the fact that ATF6␣ knockdown sensitizes D-HEp3 cells to doxorubicininduced cell death. This might occur through the up-regulation of BiP, as in D-HEp3 cells BiP protected from TOPO II inhibitors, through the inhibition of Bax (10) . Our data suggest that ATF6␣ regulates two arms of a survival pathway; one that will respond to ER-, nutritional-or chemotherapy-induced stress through BiP and another that may protect against these insults and/or microenvironment-derived stress through Rheb and mTOR. In summary, our findings reveal a pathway where ATF6␣ upregulates Rheb to activate mTOR, selectively enhancing dormant cell survival in vivo. In addition, we identified a previously unrecognized cross-talk among p38, ATF6␣, and mTOR signaling pathways that may be of general relevance because it is active in both human and mouse cells. The interaction between ATF6␣ and mTOR signaling appears to confer resistance of D-HEp3 cells to doxorubicin and to the mTOR inhibitor rapamycin, revealing a potential drug resistance mechanism. Taken together, our data identifies the ATF6␣-Rheb-mTOR axis as a new target to inhibit the survival of dormant tumor cells.
Materials and Methods
Reagents, Antibodies, and Cell Lines. For a full list of reagents and antibodies, see SI Text. T-and D-HEp3 human squamous carcinoma cells were cultured as described (7, 8) . MKK6 Ϫ/Ϫ and wt MEFs were kindly provided by Roger Davis (University of Massachusetts Medical School, Worcester). 
IF and Immunoblotting (IB).
IF for ATF6␣ and p-S6 RP was performed as described (10, 30) ; and see SI Text. For Caspase-3 IF, cells from tumor nodules in vivo were attached to poly-L-lysine (Sigma) -coated coverslips. Images were captured by using a Leica Confocal or a Nikon Eclipse TS100 microscope. In some experiments, D-HEp3 cells were treated with 10 M SB203580 for 24/48 h, and T-HEp3 cells were transfected with eGFP (Clontech) and the MKK6(E)b plasmid or with pCDNA3.1Neo (Clontech). Quantification was performed by using NIH ImageJ 1.38. IB was performed as described (8) .
Luciferase (Luc) Assays. Luc assays were performed as described (31) . The 5xATF6-GL3 and 3xFLAG-ATF6 plasmids were kindly provided by Ron Prywes (Columbia University, New York), the pcDNA3-3HA-p38␣ WT plasmid by David Engelberg (The Hebrew University of Jerusalem, Israel), the Renilla-Luc plasmid was from Clontech, and activity was assayed by using the Dual Luciferase Assay kit (Promega).
Xenograft Studies. Cells were grown on CAMs as described (8, 9) ; and see SI Text. For nude mice experiments, 0.5 ϫ 10 6 cells were inoculated s.c. in the interscapular region of 2-to 3-month-old female BALB/c nude mice (Taconic Farms). Tumor growth was measured daily by using a caliper. All experiments were approved by the State University of New York Institutional Animal Care and Use Committee.
Microarray. Four Affymetrix Hgu133a chips were run in the State University of New York (Albany, NY) Center for Functional Genomics with the following samples: two siRNA to ATF6␣ (48-h transfection) and two siRNA control. Raw data were background-corrected, normalized, and summarized by using mas5 and Genespring. Statistically significant differences were expressed as Ն1.5-fold changes in cells with ATF6␣ knockdown compared with the control.
Statistical Analysis. Statistical analysis was performed by using GraphPad Prism 5.0 for Windows from GraphPad Software. Two means were compared by using the unpaired t test or ANOVA with Bonferroni multiple comparison, whereas in vivo data were analyzed by using the Mann-Whitney or Kruskall-Wallis test followed by Dunn's multiple comparison. Survival differences were calculated by using the Mantel-Cox log-rank test. P values Ͻ0.05 were considered statistically significant.
